Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGP siRNA
- Development stage
- Preclinical
- Lead developer
- University of Colorado
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MGP siRNA is a small interfering RNA (siRNA) designed to target and knockdown the expression of matrix gla protein (MGP). In endothelial cells, knockdown of MGP has been shown to decrease the expression of von Willebrand factor (VWF) at both the mRNA and intracellular protein levels, suggesting a role for MGP in the transcriptional regulation of VWF and its potential implication in von Willebrand disease (VWD).
- Other names
- MGP small interfering RNAmatrix gla protein siRNA
02
Targets
MGP (Matrix Gla protein)
Beyond the preview
Go deeper on MGP siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGP siRNA.